Eli Lilly: The First Healthcare Colossus to Achieve $1 Trillion Valuation
Eli Lilly has made history by becoming the first healthcare company to reach a $1 trillion market capitalization. This significant achievement has been driven by the explosive demand for its weight-loss drug Zepbound and diabetes treatment Mounjaro. The pharmaceutical giant’s stock has seen a remarkable climb of more than 36% this year, with shares trading around $1,060, as investors bet on the continued growth of the GLP-1 drug market.
The company’s meteoric rise is powered by record-breaking sales figures. Mounjaro generated a whopping $6.52 billion in revenue in the third quarter alone, representing a 109% increase from the previous year. Meanwhile, Zepbound posted $3.59 billion in sales, marking a staggering 184% jump. Wall Street analysts predict the weight-loss drug market could reach $150 billion by 2030, positioning Lilly as a dominant player in this lucrative sector.
This milestone places Lilly in an exclusive club typically dominated by tech giants, making it only the second non-technology company to reach the trillion-dollar mark after Berkshire Hathaway. The achievement underscores how the obesity treatment revolution is reshaping the pharmaceutical industry and creating massive shareholder value.
Source: CNBC